| 2024-11-18 | +123.1% | M&A | Seeking Alpha | Aclaris stock rallies 53% amid licensing deal, Piper upgrade |
| 2024-11-18 | +123.1% | M&A | Seeking Alpha | Aclaris signs license deal for biologics assets |
| 2024-11-18 | +123.1% | legal | SEC EDGAR | ACRS 8-K: 1.01, 3.02, 5.02, 7.01, 8.01 (SEC Filing) |
| 2023-11-13 | -87.5% | legal | SEC EDGAR | ACRS 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-11-13 | -87.5% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2023-03-06 | -40.6% | legal | SEC EDGAR | ACRS 8-K: 8.01 and (SEC Filing) |
| 2023-03-06 | -40.6% | news | The Motley Fool | Why Aclaris Therapeutics Is Crashing Today - The Motley Fool |
| 2024-01-16 | +28.6% | news | Seeking Alpha | Aclaris spikes after leadership change, strategic review |
| 2024-01-10 | -25.8% | analyst | Seeking Alpha | Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy |
| 2024-01-10 | -25.8% | news | Seeking Alpha | Aclaris posts topline data from mid-stage trial for eczema therapy |
| 2024-11-19 | +25.7% | M&A | Seeking Alpha | Aclaris stock soars for second day on licensing deal, analyst upgrades |
| 2024-11-19 | +25.7% | analyst | Yahoo Finance | Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Yahoo Finance |
| 2021-06-08 | -20.5% | legal | SEC EDGAR | ACRS 8-K: 7.01, 8.01 (SEC Filing) |
| 2022-08-03 | +16.6% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2026-03-31 | +14.9% | earnings | MarketBeat | Aclaris Therapeutics' (ACRS) Outperform Rating Reaffirmed at Wedbush - MarketBeat |
| 2026-01-26 | -14.9% | news | simplywall.st | Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - simplywall.st |
| 2025-10-15 | +13.5% | news | Seeking Alpha | Aclaris Therapeutics, Inc. (ACRS) Discusses At 2025 R&D Day (Transcript) |
| 2021-11-02 | -13.4% | legal | SEC EDGAR | ACRS 8-K: 2.02, 5.02 (SEC Filing) |
| 2022-11-29 | -13.4% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Aclaris Therapeutics (ACRS) - Zacks Investment Research |
| 2025-10-21 | +13.0% | news | Yahoo Finance | What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now? - Yahoo Finance |
| 2024-12-19 | -12.5% | news | Seeking Alpha | Aclaris Therapeutics files to sell 35.56M shares of common stock by selling shareholders |
| 2023-08-07 | -12.5% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | -12.3% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$0.16 misses by $0.02, revenue of $1.3M misses by $0.77M |
| 2026-02-26 | -12.3% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | -12.3% | news | Yahoo Finance | Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance |
| 2026-02-26 | -12.3% | earnings | Yahoo Finance | Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance |
| 2024-01-22 | +11.8% | news | Seeking Alpha | HW Wainwright cuts Aclaris to neutral, cites underwhelming study data |
| 2026-01-28 | -11.2% | analyst | Investing.com | Aclaris stock gets Buy rating reaffirmed by H.C. Wainwright after positive preclinical results - Investing.com |
| 2022-02-24 | +10.6% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2026-04-03 | -10.0% | news | UBND thành phố Hải Phòng | ACRS Stock Analysis: Aclaris Therapeutics Inc biotech stock gains 1.45 percent at 4.2 dollars - UBND thành phố Hải Phòng |
| 2021-06-11 | -9.7% | legal | SEC EDGAR | ACRS 8-K: 1.01, 8.01 (SEC Filing) |
| 2024-05-08 | -9.2% | earnings | Seeking Alpha | Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript |
| 2025-02-11 | -9.0% | M&A | Seeking Alpha | Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule |
| 2025-02-11 | -9.0% | M&A | Seeking Alpha | Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule - Seeking Alpha |
| 2025-07-29 | -8.5% | legal | SEC EDGAR | ACRS 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-01-27 | -8.5% | news | Stock Titan | Aclaris oral compound restores 93% hair in severe alopecia mice - Stock Titan |
| 2026-01-27 | -8.5% | news | GlobeNewswire | Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 - GlobeNewswire |
| 2024-01-11 | -8.1% | analyst | Seeking Alpha | Aclaris draws second downgrade despite Phase 2 win for eczema therapy |
| 2022-05-10 | -7.5% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2023-05-08 | -7.4% | legal | SEC EDGAR | ACRS 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-11-06 | +7.1% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$0.11 misses by $0.05, revenue of $4.35M misses by $7.5M |
| 2024-11-06 | +7.1% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2024-05-07 | -7.0% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$0.24 beats by $0.03, revenue of $2.4M beats by $0.4M |
| 2024-05-07 | -7.0% | legal | SEC EDGAR | ACRS 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-08-01 | -6.9% | legal | SEC EDGAR | ACRS 8-K: 5.02 and (SEC Filing) |
| 2026-04-16 | +6.7% | analyst | MT Newswires | Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target |
| 2026-04-16 | +6.7% | analyst | MSN | Oppenheimer initiates coverage of Aclaris Therapeutics (ACRS) with outperform recommendation - MSN |
| 2026-03-10 | +6.5% | news | MarketBeat | Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference |
| 2026-03-10 | +6.5% | news | TradingView | Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering - TradingView |
| 2026-03-10 | +6.5% | news | TipRanks | Aclaris Therapeutics Raises Capital via Institutional Stock Sale - TipRanks |
| 2026-03-10 | +6.5% | news | StocksToTrade | Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles - StocksToTrade |
| 2026-03-10 | +6.5% | news | timothysykes.com | Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com |
| 2024-11-20 | -6.5% | M&A | Seeking Alpha | Aclaris upgraded to overweight by Cantor on in-licensing deal |
| 2025-04-25 | +6.3% | news | Stock Titan | ACRS Stock Price, News & Analysis - Stock Titan |
| 2022-11-08 | +5.8% | legal | SEC EDGAR | ACRS 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-08-07 | -5.7% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$0.15, revenue of $2.8M |
| 2024-08-07 | -5.7% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2024-02-05 | -5.7% | legal | SEC EDGAR | ACRS 8-K: 5.02 (SEC Filing) |
| 2026-04-08 | +5.7% | news | GlobeNewswire | Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference |
| 2026-04-08 | +5.7% | executive | Stock Titan | Aclaris CEO joins Apr. 14 skin disease conference webcast - Stock Titan |
| 2025-06-05 | -5.5% | legal | SEC EDGAR | ACRS 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2024-01-19 | +5.3% | legal | SEC EDGAR | ACRS 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-04-13 | -5.2% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is Aclaris (ACRS) Stock Attractive Now | Price at $4.00, Down 1.11% - Turnaround Stocks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-02-27 | -5.2% | news | Seeking Alpha | Aclaris Therapeutics plans $300M mixed shelf offering |
| 2025-02-27 | -5.2% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$1.01 misses by $0.78, revenue of $9.21M beats by $2.17M |
| 2025-02-27 | -5.2% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2022-01-14 | -5.0% | legal | SEC EDGAR | ACRS 8-K: 5.02 and (SEC Filing) |
| 2022-11-22 | -4.9% | legal | SEC EDGAR | ACRS 8-K: 5.02 (SEC Filing) |
| 2023-01-06 | +4.9% | legal | SEC EDGAR | ACRS 8-K: 5.02 (SEC Filing) |
| 2025-06-30 | -4.5% | news | Seeking Alpha | Aclaris Therapeutics joins Russell 3000 and Russell 2000 Indexes |
| 2025-08-07 | +4.5% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$0.13 in-line, revenue of $1.77M beats by $0.48M |
| 2025-08-07 | +4.5% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2023-02-23 | -4.3% | legal | SEC EDGAR | ACRS 8-K: 1.01, 1.02 (SEC Filing) |
| 2023-02-23 | -4.3% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2025-11-06 | +3.6% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$0.12 beats by $0.02, revenue of $3.3M beats by $1.89M |
| 2025-11-06 | +3.6% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2026-03-20 | -3.6% | news | GlobeNewswire | Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting |
| 2026-03-20 | -3.6% | news | Stock Titan | New eczema trial results from Aclaris will debut at dermatology meeting - Stock Titan |
| 2026-03-20 | -3.6% | news | Quiver Quantitative | Aclaris Therapeutics Announces ePoster Presentation on Phase 2a Trial Results of ATI-2138 for Moderate-to-Severe Atopic Dermatitis at AAD Annual Meeting 2026 - Quiver Quantitative |
| 2026-03-20 | -3.6% | news | parameter.io | Aclaris Therapeutics, Inc. (ACRS) Stock: Advances Pipeline with New ATI-2138 Results at AAD 2026 - parameter.io |
| 2022-12-13 | +3.6% | legal | SEC EDGAR | ACRS 8-K: 5.02 (SEC Filing) |
| 2021-08-05 | +3.3% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2023-06-01 | +2.9% | legal | SEC EDGAR | ACRS 8-K: 1.01 and (SEC Filing) |
| 2025-12-21 | -2.9% | news | Trefis | Can Aclaris Therapeutics Stock Hold Up When Markets Turn? - Trefis |
| 2021-05-20 | -2.8% | legal | SEC EDGAR | ACRS 8-K: 1.01 and (SEC Filing) |
| 2026-01-12 | +2.7% | news | Stock Titan | Experimental atopic dermatitis drug begins new safety trial in patients - Stock Titan |
| 2024-05-06 | -2.6% | earnings | Seeking Alpha | Aclaris Therapeutics Q1 2024 Earnings Preview |
| 2025-11-20 | +2.6% | news | Yahoo Finance | Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks - Yahoo Finance |
| 2026-04-23 | -2.4% | executive | Quiver Quantitative | Aclaris Therapeutics, Inc. ($ACRS) CEO 2025 Pay Revealed - Quiver Quantitative |
| 2026-04-23 | -2.4% | news | Stock Titan | Executive pay, board elections in Aclaris Therapeutics (NASDAQ: ACRS) 2026 proxy - Stock Titan |
| 2024-03-19 | +2.0% | legal | SEC EDGAR | ACRS 8-K: 5.02 (SEC Filing) |
| 2026-03-18 | -2.0% | news | MT Newswires | Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Potential Dermatitis Treatment |
| 2026-03-18 | -2.0% | news | GlobeNewswire | Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis |
| 2026-03-18 | -2.0% | earnings | Stock Titan | 109-patient atopic dermatitis trial filled; results coming Q4 2026 - Stock Titan |
| 2021-05-07 | -1.9% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2026-03-03 | +1.8% | news | GlobeNewswire | Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference |
| 2024-02-27 | -1.7% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55M |
| 2024-02-27 | -1.7% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2025-12-19 | -1.6% | news | Quiver Quantitative | Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025 - Quiver Quantitative |
| 2025-12-19 | -1.6% | news | GlobeNewswire | Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - GlobeNewswire |
| 2025-12-19 | -1.6% | news | Kalkine Media | Aclaris Therapeutics (NASDAQ:ACRS) Nasdaq Top 100 Biotech Model - Kalkine Media |
| 2026-03-26 | +1.5% | news | Zacks | Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? |
| 2024-07-16 | -1.4% | news | Seeking Alpha | Aclaris sells OLUMIANT royalties and milestones to OMERS life sciences |
| 2024-07-16 | -1.4% | legal | SEC EDGAR | ACRS 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-09-04 | +1.4% | news | simplywall.st | Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans? - simplywall.st |
| 2026-04-07 | +1.4% | news | Stock Titan | RA Capital Group reports 7.63M Aclaris shares (NASDAQ: ACRS) - Stock Titan |
| 2026-04-14 | -1.2% | news | MarketBeat | Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming |
| 2026-04-14 | -1.2% | earnings | MarketBeat | Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4% - MarketBeat |
| 2026-03-27 | +1.2% | news | GlobeNewswire | Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 |
| 2026-03-27 | +1.2% | news | Stock Titan | Experimental eczema pill cut disease severity 77% in 12-week trial - Stock Titan |
| 2025-04-22 | +1.1% | legal | Seeking Alpha | Aclaris Therapeutics gets FDA nod to begin trial of ATI-052 |
| 2026-04-20 | -1.0% | news | Cổng thông tin điện tử tỉnh Lào Cai | Aclaris (ACRS) Stock Gap Down Watch (Investor Interest) 2026-04-20 - Stock Analysis Community - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-01-06 | +0.9% | news | Seeking Alpha | Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages - Slideshow |
| 2026-01-06 | +0.9% | news | Seeking Alpha | Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript |
| 2026-01-06 | +0.9% | legal | SEC EDGAR | ACRS 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-01-06 | +0.9% | news | GlobeNewswire | Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - GlobeNewswire |
| 2023-06-12 | -0.8% | legal | SEC EDGAR | ACRS 8-K: 5.02 and (SEC Filing) |
| 2025-08-10 | +0.8% | earnings | Yahoo Finance | Earnings Beat: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance |
| 2025-08-10 | +0.8% | earnings | simplywall.st | Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st |
| 2025-10-14 | +0.7% | news | Seeking Alpha | Aclaris Therapeutics, Inc. (ACRS) Special Call - Slideshow |
| 2026-02-03 | -0.6% | news | simplywall.st | There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump - simplywall.st |
| 2025-10-12 | +0.6% | news | Yahoo Finance | Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? - Yahoo Finance |
| 2026-02-04 | -0.6% | news | Yahoo Finance | Aclaris Therapeutics to Participate in Two February Healthcare Conferences - Yahoo Finance |
| 2026-01-21 | +0.6% | news | Moomoo | There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 41% Price Jump - Moomoo |
| 2026-04-15 | +0.5% | news | Cổng thông tin điện tử Tỉnh Sơn La | Aclaris (ACRS) Stock: Momentum Shift (Marginal Gain) 2026-04-15 - Fast Rising Stocks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2023-11-06 | +0.4% | legal | SEC EDGAR | ACRS 8-K: 2.02 and (SEC Filing) |
| 2023-03-27 | +0.4% | legal | SEC EDGAR | ACRS 8-K: 5.02 and (SEC Filing) |
| 2025-05-08 | +0.2% | earnings | Seeking Alpha | Aclaris Therapeutics GAAP EPS of -$0.12, revenue of $1.46M |
| 2025-05-08 | +0.2% | legal | SEC EDGAR | ACRS 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-07-15 | +0.1% | news | Yahoo Finance | Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Yahoo Finance |